tubercle bacillus

So the tubercle bacillus is a particularly difficult target for chemical attack.

The statistics tell us that one third of the world's population is infected with the tubercle bacillus.

According to recent estimates, around two billion people are infected with the tubercle bacillus, or in other words one third of the world's population.

Such is no longer the case since scientists came up with the agents to tame and destroy the tubercle bacillus.

Every second, the tubercle bacillus claims another victim.

Some of the ways the tubercle bacillus acquires drug resistance are:

Koch identified the tubercle bacillus only in 1882.

We are not likely to find a cause as precisely as the tubercle bacillus can be shown to produce tuberculosis.

Tuberculin is a glycerol extract of the tubercle bacillus.

German bacteriologist Robert Koch had discovered the tubercle bacillus in 1882, but the best treatment was not yet clear.

True, the symptoms appeared to indicate that it was the tubercle bacillus at work in Broni's lungs.

Their work included subculturing virulent strains of the tubercle bacillus and testing different culture media.

In all likelihood, the tubercle bacillus was never transported across interstellar space, at least not in an active state."

His efforts to make progress with the tubercle bacillus came to a standstill until he tackled its tough (lipid) capsule.

See Tubercle bacillus.

After the tubercle bacillus was identified, accurate diagnosis of tuberculosis, of the lungs and of other organs, became possible.

Before Robert Koch discovered the tubercle bacillus in 1882, theories ascribed tuberculosis to everything from stress to genes to bad air.

In 1882, Koch reported identification of the tubercle bacillus as the cause of tuberculosis, cementing germ theory.

The discovery seems to explain how isoniazid, a key antituberculosis drug, kills the tubercle bacillus.

Franz Ziehl introduced the carbolfuchsin stain for the tubercle bacillus in 1882.

Tubercle bacillus is inhibited by copper as simple cations or complex anions in concentrations from 0.02 to 0.2 g/L.

He became a research fellow at Leeds School of Medicine after the war, working with tubercle bacillus and diphtheria toxins.

Every time human scientists developed a new and stronger antibiotic to treat the tubercle bacillus, the bacillus evolved a resistant strain.

Unfortunately, he selected M chelonei (the turtle tubercle bacillus), one of the two rapid growers pathogenic for humans.

Mycobacterium tuberculosis (tubercle bacillus)